Press Release January 28, 2020

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

The Life Sciences team advised Quench Bio through the completion of a $50 million Series A financing led by RA Capital Management, with participation from new investor Abbvie Ventures. Atlas Venture and Arix Bioscience plc who co-founded and seeded the company, also participated in the Series A.

Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Quench's lead compounds target and inhibit the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs. Quench Bio launched in January 2020 with $50 million from leading life science investors including Atlas Venture, Arix Bioscience, RA Capital and AbbVie Ventures.

The Goodwin team advising Quench Bio since its formation is led by partners Bill Collins and Sarah Solomon and includes associates Gabriela Morales-Rivera and Tyler Vandeventer.

For additional information, read the press release and articles in Fierce Biotech and Venture Capital Journal.